Palisade Bio Inc. (PALI) Appoints Brian Feagan to its Board
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- Wall Street sinks as Nasdaq falls over 2% on AI cost worries
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
Palisade Bio Appoints Brian Feagan, MD, FRCPC, to its Clinical Advisory Board
December 17, 2024 8:30 AM ESTCarlsbad, CA, Dec. 17, 2024 (GLOBE NEWSWIRE) -- Â Palisade Bio, Inc. (Nasdaq: PALI) (Palisade, Palisade Bio or the Company), a clinical-stage biopharmaceutical company focused on developing novel therapeutics for patients with autoimmune, inflammatory, and fibrotic diseases, today announced the appointment of Brian G. Feagan, MD, FRCPC, to its Clinical Advisory Board.
... More


